ArticleRSC advances2022
Photoactive Zr-aromatic hybrid thin films made by molecular layer deposition.
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The principle of antimicrobial photodynamic therapy (PDT) is appealing because it can be controlled by an external light source and possibly the use of durable materials. However, to utilise such surfaces requires a process for their production that allows for coating on even complex geometries. We have therefore explored the ability of the emerging molecular layer deposition (MLD) technique to produce and tune PDT active materials. This study demonstrates how the type of aromatic ligand influences the optical and antimicrobial properties of photoactive Zr-organic hybrid thin films made by MLD. The three aromatic dicarboxylic acids: 2,5-dihydroxy-1,4-benzenedicarboxylic acid, 2-amino-1,4-benzenedicarboxylic acid and 2,6-naphthalenedicarboxylic acid have been combined with ZrCl
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.